| ²é¿´: 433 | »Ø¸´: 2 | ||
| ¡¾ÐüÉͽð±Ò¡¿»Ø´ð±¾ÌûÎÊÌ⣬×÷Õ߻ƻÆ516½«ÔùËÍÄú 5 ¸ö½ð±Ò | ||
[ÇóÖú]
Blood ¹ØÓÚZUMA7Ñо¿½á¹û
|
||
|
Âé·³°ïæÕÒÒ»ÏÂÔÎÄ ·¢×ÔСľ³æIOS¿Í»§¶Ë |
» ²ÂÄãϲ»¶
²ÄÁϹ¤³Ì281»¹Óе÷¼Á»ú»áÂð
ÒѾÓÐ15È˻ظ´
Ò»Ö¾Ô¸Ïôó0856£¬306Çóµ÷¼Á
ÒѾÓÐ14È˻ظ´
271Çóµ÷¼Á
ÒѾÓÐ18È˻ظ´
ɽ¶«¸ßУ½Ìʦ¿¼ºË³¬¼¶ÎÞµ×Ïߣ¬Ô±¹¤¹ý²»ÏÂÈ¥À²
ÒѾÓÐ8È˻ظ´
ÓÐûÓÐѧУ²ÄÁÏרҵÊÕ¿çµ÷(Ò»Ö¾Ô¸085410)
ÒѾÓÐ9È˻ظ´
280Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
344 ²ÄÁÏרҵ Çóµ÷¼Á211 ÎÞµØÓòÒªÇó
ÒѾÓÐ3È˻ظ´
µ÷¼Á
ÒѾÓÐ6È˻ظ´
290Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
0854µ÷¼Á
ÒѾÓÐ9È˻ظ´
|
Blood. 2022 Nov 24;140(21):2248-2260Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma ·¢×ÔСľ³æIOS¿Í»§¶Ë |
2Â¥2024-01-23 10:21:49
3Â¥2024-01-23 10:22:09













»Ø¸´´ËÂ¥